Xenetic Biosciences, Inc. (XBIO) Income Statement
XBIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsXBIO revenue and net income
Where XBIO's revenue goes
2025Each bar shows an amount and its share of revenue. XBIO kept −90.1% of revenue as net income.
XBIO profit margins
XBIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +19.0% | +20.4% | +46.8% | — |
| Gross profit | +19.0% | +20.4% | +46.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XBIO quarterly EPS vs estimates
Xenetic Biosciences beat the analyst EPS estimate in 4 of the last 6 quarters. Next report: November 11, 2026.
XBIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436,942 | $17,066 | $0 | $7.6M | $3.0M |
| Cost of revenue | $0 | $0 | $0 | $27,043 | $35,482 | $0 | $0 | $15,827 | $156,119 | $36,449 |
| Gross profit | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436,942 | $17,066 | −$15,827 | $7.4M | $3.0M |
| Research & development | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M | $1.7M | $4.9M | $2.9M | $4.1M | $43.7M |
| Sales, general & admin | $2.7M | $3.4M | $3.6M | $3.7M | $3.7M | $3.4M | $4.7M | $4.4M | $6.9M | $6.7M |
| Total operating expenses | $5.8M | $6.7M | $7.1M | $8.4M | $6.9M | $14.4M | $12.9M | $7.3M | $11.0M | $50.4M |
| Operating income | −$2.8M | −$4.2M | −$4.5M | −$6.7M | −$5.7M | −$13.9M | −$12.9M | −$7.3M | −$3.6M | −$47.4M |
| Interest income | $147,997 | $249,861 | $351,807 | $167,152 | $100,467 | $126,171 | $108,490 | $510 | $16,544 | $32 |
| Interest expense | — | — | — | $165,555 | $101,586 | $18.4M | $111,804 | $24,131 | $1,818 | $729,572 |
| Income before taxes | −$2.7M | −$4.0M | −$4.1M | −$6.6M | −$5.6M | −$13.8M | −$12.8M | −$7.3M | −$3.6M | −$54.2M |
| Income taxes | — | — | $28,207 | −$165,555 | −$100,467 | −$2.9M | $3.2M | $24,131 | $26,370 | $6.0M |
| Net income | −$2.7M | −$4.0M | −$4.1M | −$6.6M | −$5.6M | −$10.9M | −$12.8M | −$7.3M | −$3.6M | −$54.2M |
| EBITDA | −$2.7M | −$3.8M | −$4.1M | −$6.5M | −$5.6M | −$4.7M | −$9.6M | −$7.3M | −$3.6M | −$53.4M |
| EPS (diluted) | −$1.59 | −$2.57 | −$2.75 | −$3.80 | −$4.24 | −$4.98 | −$3.39 | −$2.87 | −$113.06 | −$838.22 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 97.9% | 98.8% |
| Operating margin | −95.2% | −168.2% | −177.8% | −393.6% | −495.1% | −3,189.8% | −75,511.7% | — | −47.1% | −1,581.0% |
| Net margin | −90.1% | −158.4% | −162.8% | −383.9% | −486.4% | −2,493.1% | −74,856.6% | — | −47.4% | −1,806.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $660,601 | $806,923 | $766,296 | $1.0M | $589,897 | $593,261 | $648,820 | $614,243 | $726,404 | $510,816 | $671,963 | $611,174 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $660,601 | $806,923 | $766,296 | $1.0M | $589,897 | $593,261 | $648,820 | $614,243 | $726,404 | $510,816 | $671,963 | $611,174 |
| Research & development | $552,013 | $661,443 | $773,416 | $756,482 | $656,557 | $879,029 | $1.0M | $367,985 | $933,771 | $944,321 | $975,628 | $1.0M |
| Sales, general & admin | $1.1M | $647,597 | $615,907 | $815,209 | $657,752 | $656,641 | $705,710 | $745,731 | $1.1M | $834,910 | $952,002 | $737,241 |
| Total operating expenses | $1.6M | $1.3M | $1.4M | $1.6M | $1.3M | $1.5M | $1.7M | $1.1M | $2.1M | $1.8M | $1.9M | $1.8M |
| Operating income | −$971,690 | −$502,117 | −$623,027 | −$544,734 | −$724,412 | −$942,409 | −$1.1M | −$499,473 | −$1.3M | −$1.3M | −$1.3M | −$1.1M |
| Interest income | $42,067 | $45,756 | $43,792 | $30,783 | $34,232 | $39,190 | $51,867 | $61,298 | $63,447 | $73,249 | $83,757 | $91,796 |
| Interest expense | — | — | — | — | — | — | — | — | — | $58,621 | $58,621 | — |
| Income before taxes | −$929,695 | −$456,382 | −$579,076 | −$509,939 | −$688,703 | −$903,141 | −$1.1M | −$436,671 | −$1.3M | −$1.2M | −$1.2M | −$1.1M |
| Income taxes | — | — | — | — | — | −$10,624 | — | −$436,671 | −$18,980 | $10,624 | $7,849 | −$99,436 |
| Net income | −$929,695 | −$456,382 | −$579,076 | −$509,939 | −$688,703 | −$903,141 | −$1.1M | −$436,671 | −$1.3M | −$1.2M | −$1.2M | −$1.1M |
| EBITDA | −$929,695 | −$456,382 | −$579,076 | −$509,939 | −$688,703 | −$903,141 | −$1.1M | −$436,671 | −$1.3M | −$1.2M | −$1.3M | −$1.0M |
| EPS (diluted) | −$0.41 | −$0.20 | −$0.22 | −$0.33 | −$0.45 | −$0.59 | −$0.68 | −$0.28 | −$0.83 | −$0.78 | −$0.77 | −$0.69 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −147.1% | −62.2% | −81.3% | −53.0% | −122.8% | −158.9% | −169.4% | −81.3% | −184.1% | −248.3% | −186.9% | −187.6% |
| Net margin | −140.7% | −56.6% | −75.6% | −49.7% | −116.7% | −152.2% | −162.5% | −71.1% | −175.4% | −234.0% | −174.3% | −172.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XBIO's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XBIO financial results
In fiscal year 2025 (ended December 31, 2025), Xenetic Biosciences reported revenue of $3.0 million, up 19.0% from the year before. It had a net loss of $2.7 million, a net profit margin of −90.1%. Diluted earnings per share came to −$1.59. Over five years revenue grew at an average rate of 46.8% a year.
See the XBIO stock overview for the latest quote and news, or the XBIO chart for price history and technical indicators.
XBIO income statement FAQ
What is Xenetic Biosciences's annual revenue?
Xenetic Biosciences reported total revenue of $3.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 19.0% from $2.5 million the previous year.
Is Xenetic Biosciences profitable?
No. Xenetic Biosciences reported a net loss of $2.7 million in fiscal 2025, a net profit margin of −90.1%; its operating margin was −95.2%.
What is Xenetic Biosciences's gross margin?
Xenetic Biosciences's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Xenetic Biosciences kept $100 after the direct cost of its products and services.
How much does Xenetic Biosciences spend on research and development?
Xenetic Biosciences spent $3.1 million on research and development in fiscal 2025, 103.0% of revenue.
How fast is Xenetic Biosciences growing?
Revenue grew 46.8% a year on average over the last five fiscal years, from $0.4 million to $3.0 million.
What are Xenetic Biosciences's earnings per share?
Xenetic Biosciences earned $-1.59 per diluted share in fiscal 2025, compared with $-2.57 a year earlier.
When will Xenetic Biosciences report its next earnings?
Xenetic Biosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Xenetic Biosciences's fiscal year end?
Xenetic Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.